KR20190096409A - 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 - Google Patents

불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 Download PDF

Info

Publication number
KR20190096409A
KR20190096409A KR1020197021162A KR20197021162A KR20190096409A KR 20190096409 A KR20190096409 A KR 20190096409A KR 1020197021162 A KR1020197021162 A KR 1020197021162A KR 20197021162 A KR20197021162 A KR 20197021162A KR 20190096409 A KR20190096409 A KR 20190096409A
Authority
KR
South Korea
Prior art keywords
ser
val
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197021162A
Other languages
English (en)
Korean (ko)
Inventor
우베 융커
미하엘라 크나이쎌
안소니 켄트 홀
레나 조이 유디
매튜 매닝 릭스
Original Assignee
메레오 바이오파마 3 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메레오 바이오파마 3 리미티드 filed Critical 메레오 바이오파마 3 리미티드
Priority to KR1020227011791A priority Critical patent/KR20220051269A/ko
Publication of KR20190096409A publication Critical patent/KR20190096409A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197021162A 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 Ceased KR20190096409A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227011791A KR20220051269A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437353P 2016-12-21 2016-12-21
US62/437,353 2016-12-21
PCT/GB2017/053850 WO2018115880A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011791A Division KR20220051269A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도

Publications (1)

Publication Number Publication Date
KR20190096409A true KR20190096409A (ko) 2019-08-19

Family

ID=60915566

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247023410A Ceased KR20240113615A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
KR1020197021162A Ceased KR20190096409A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
KR1020227011791A Ceased KR20220051269A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247023410A Ceased KR20240113615A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227011791A Ceased KR20220051269A (ko) 2016-12-21 2017-12-21 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도

Country Status (23)

Country Link
US (5) US20200179509A1 (enExample)
EP (2) EP3868780A1 (enExample)
JP (3) JP7050335B2 (enExample)
KR (3) KR20240113615A (enExample)
CN (2) CN117442720A (enExample)
AU (1) AU2017381433B2 (enExample)
BR (1) BR112019012731A2 (enExample)
CA (1) CA3047221A1 (enExample)
CL (1) CL2019001749A1 (enExample)
CY (1) CY1124238T1 (enExample)
DK (1) DK3478719T6 (enExample)
ES (1) ES2862922T7 (enExample)
FI (1) FI3478719T6 (enExample)
HR (1) HRP20210207T4 (enExample)
HU (1) HUE053436T2 (enExample)
IL (1) IL267430B1 (enExample)
LT (1) LT3478719T (enExample)
MX (1) MX2019007161A (enExample)
NZ (1) NZ754676A (enExample)
PL (1) PL3478719T6 (enExample)
PT (1) PT3478719T (enExample)
SI (1) SI3478719T2 (enExample)
WO (1) WO2018115880A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220023026A (ko) * 2020-08-20 2022-03-02 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
AU2017381433B2 (en) * 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN112166120B (zh) 2018-03-30 2024-09-10 安姆根有限公司 C末端抗体变体
EP3807266B1 (en) 2018-06-18 2023-10-25 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
AU2022357544A1 (en) * 2021-09-30 2024-04-11 Mereo Biopharma 3 Limited Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ512122A (en) 1998-11-27 2003-12-19 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
UA96474C2 (en) * 2007-03-20 2011-11-10 Эли Лилли Энд Компани Anti-sclerostin antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
EP2558106A1 (en) * 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
MX355060B (es) * 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AU2017381433B2 (en) * 2016-12-21 2024-11-14 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2020502218A (ja) * 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220023026A (ko) * 2020-08-20 2022-03-02 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법

Also Published As

Publication number Publication date
CL2019001749A1 (es) 2019-12-27
CA3047221A1 (en) 2018-06-28
US20230365669A1 (en) 2023-11-16
DK3478719T6 (da) 2025-01-20
US20210253684A1 (en) 2021-08-19
EP3868780A1 (en) 2021-08-25
CN110325548B (zh) 2023-11-17
RU2019118719A (ru) 2021-01-22
HUE053436T2 (hu) 2021-06-28
ES2862922T7 (en) 2025-02-26
JP2025020150A (ja) 2025-02-12
US20200179509A1 (en) 2020-06-11
ES2862922T3 (es) 2021-10-08
US20240400666A1 (en) 2024-12-05
WO2018115880A1 (en) 2018-06-28
RU2019118719A3 (enExample) 2021-06-01
SI3478719T1 (sl) 2021-09-30
IL267430A (en) 2019-08-29
SI3478719T2 (sl) 2025-07-31
EP3478719B1 (en) 2021-01-20
CN117442720A (zh) 2024-01-26
IL267430B1 (en) 2025-09-01
DK3478719T3 (da) 2021-03-01
US20200123242A1 (en) 2020-04-23
MX2019007161A (es) 2020-02-12
FI3478719T6 (fi) 2025-01-20
JP7050335B2 (ja) 2022-04-08
LT3478719T (lt) 2021-04-12
KR20220051269A (ko) 2022-04-26
EP3478719A1 (en) 2019-05-08
JP2020502219A (ja) 2020-01-23
KR20240113615A (ko) 2024-07-22
CN110325548A (zh) 2019-10-11
PL3478719T6 (pl) 2025-01-27
BR112019012731A2 (pt) 2019-11-26
EP3478719B3 (en) 2024-12-18
AU2017381433A1 (en) 2019-07-04
AU2017381433B2 (en) 2024-11-14
CY1124238T1 (el) 2022-07-22
JP2022046529A (ja) 2022-03-23
HRP20210207T4 (hr) 2025-01-31
PL3478719T3 (pl) 2021-10-25
HRP20210207T1 (hr) 2021-03-19
PT3478719T (pt) 2021-03-18
NZ754676A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
AU2017381433B2 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2020340881B2 (en) Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
RU2754369C2 (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
KR102844773B1 (ko) 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
KR102121678B1 (ko) β-KLOTHO, FGF 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
TW200922621A (en) Compositions and methods of use for antibodies against sclerostin
KR20190104158A (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
EA033369B1 (ru) Мутантные полипептиды интерлейкина-2 со сниженной аффинностью к высокоаффинному рецептору il-2 и неизменной аффинностью к рецептору il-2 с промежуточной аффинностью и их применение
CN109311973A (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
EA032828B1 (ru) Иммунотерапевтические средства против комплекса tcr
KR20170040249A (ko) 항-cdh6 항체 약물 접합체
AU2016283344A1 (en) Fusion protein containing BDNF
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20220002972A (ko) 변형 항 pd-l1 항체 및 신경변성 질환 치료 방법 및 용도
TW202216743A (zh) Ｉｌ－１０突變蛋白及其融合蛋白
CN114096561A (zh) 使用交叉双重可变结构域(codv)形式用于治疗hiv感染的三特异性和/或三价结合蛋白
RU2789033C2 (ru) Применение антител к склеростину для лечения несовершенного остеогенеза
RU2840013C1 (ru) Способ получения конъюгата антитело-лекарственное средство на основе эрибулина
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
HK40044689A (en) Mutant interleukin-2 polypeptides
HK40058067B (zh) 抗埃博拉病毒单克隆抗体、其制备方法及用途
KR20200018643A (ko) 면역 혈소판감소증의 치료 방법
TW202539736A (zh) 對胃抑肽受體(gipr)具特異性之抗原結合蛋白之用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201215

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20201215

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210420

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210420

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211130

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210824

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201215

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220308

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220208

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211130

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210824

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210420

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201215

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220408

PJ0201 Trial against decision of rejection

Patent event date: 20220408

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220308

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20211130

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220728

Appeal identifier: 2022101000802

Request date: 20220408

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101000802; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220408

Effective date: 20220728

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20220728

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220408

Decision date: 20220728

Appeal identifier: 2022101000802

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220825

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20220825

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2022101000802

Request date: 20220408

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220728

WITB Written withdrawal of application